Aerovate Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $518.68 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aerovate Therapeutics Inc had its IPO on 2021-06-30 under the ticker symbol AVTE.
The company operates in the Healthcare sector and Biotechnology industry. Aerovate Therapeutics Inc has a staff strength of 33 employees.
Shares of Aerovate Therapeutics Inc opened at $21.08 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $20.41 - $21.67, and closed at $21.67.
This is a +2.8% increase from the previous day's closing price.
A total volume of 44,668 shares were traded at the close of the day’s session.
In the last one week, shares of Aerovate Therapeutics Inc have slipped by -1.41%.
Aerovate Therapeutics Inc's Key Ratios
Aerovate Therapeutics Inc has a market cap of $518.68 million, indicating a price to book ratio of 4.5483 and a price to sales ratio of 0.
In the last 12-months Aerovate Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-45597000. The EBITDA ratio measures Aerovate Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aerovate Therapeutics Inc’s operating margin was 0% while its return on assets stood at -17.2% with a return of equity of -28.03%.
In Q3, Aerovate Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aerovate Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aerovate Therapeutics Inc’s profitability.
Aerovate Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -10.778. Its price to sales ratio in the trailing 12-months stood at 0.
Aerovate Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $147.66 million
- Total Liabilities
- $7.71 million
- Operating Cash Flow
- $4.65 million
- Capital Expenditure
- Dividend Payout Ratio
Aerovate Therapeutics Inc ended 2023 with $147.66 million in total assets and $0 in total liabilities. Its intangible assets were valued at $147.66 million while shareholder equity stood at $139.14 million.
Aerovate Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.71 million in other current liabilities, 2000.00 in common stock, $-72881000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $22.42 million and cash and short-term investments were $142.58 million. The company’s total short-term debt was $379,000 while long-term debt stood at $0.
Aerovate Therapeutics Inc’s total current assets stands at $145.16 million while long-term investments were $0 and short-term investments were $120.16 million. Its net receivables were $0 compared to accounts payable of $4.54 million and inventory worth $0.
In 2023, Aerovate Therapeutics Inc's operating cash flow was $4.65 million while its capital expenditure stood at $33000.
Comparatively, Aerovate Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aerovate Therapeutics Inc stock is currently trading at $21.67 per share. It touched a 52-week high of $30.79 and a 52-week low of $30.79. Analysts tracking the stock have a 12-month average target price of $33.8.
Its 50-day moving average was $23.84 and 200-day moving average was $20.52 The short ratio stood at 7.49 indicating a short percent outstanding of 0%.
Around 23.9% of the company’s stock are held by insiders while 11147.1% are held by institutions.
Frequently Asked Questions About Aerovate Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.